Chimera induced protein degradation: PROTACs and beyond

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Drug Discovery

Background:

• The ubiquitin-proteasome system, autophagy-lysosome pathway, and N-end rule pathway are vital cellular protein quality control mechanisms.
• Targeting these endogenous degradation pathways offers a revolutionary strategy for small-molecule drug discovery.

Purpose of the Study:

• To review the development of chimera degraders that exploit the ubiquitin-proteasome, autophagy-lysosome, and N-end rule pathways.
• To analyze the chemical structures of these degraders and their influence on biological effects from a medicinal chemistry perspective.

Main Methods:

• Literature review of chimera degrader development.
• Analysis of chemical structures and their correlation with biological activity.
• Focus on PROTACs as advanced examples of chimera degraders.

Main Results:

• PROTACs represent the most advanced chimera degraders, with two candidates in clinical trials.
• Development of chimera degraders targeting the ubiquitin-proteasome, autophagy-lysosome, and N-end rule pathways is advancing.
• Chemical structure plays a critical role in the biological efficacy of these degraders.

Conclusions:

• Chimera degraders offer a promising therapeutic strategy by hijacking endogenous protein degradation systems.
• Further research into chemical structures is essential for optimizing the biological effects of these novel drug candidates.
• Exploiting multiple protein degradation pathways expands the potential of chimera degrader technology in medicine.